Equities

Chengdu Olymvax Biopharmaceuticals Inc

688319:SHH

Chengdu Olymvax Biopharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)9.90
  • Today's Change-0.10 / -1.00%
  • Shares traded1.61m
  • 1 Year change-53.65%
  • Beta--
Data delayed at least 15 minutes, as of Jun 17 2024 08:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Chengdu Olymvax Biopharmaceuticals Inc is a China-based biopharmaceutical company mainly engaged in the research, development, production and sales of human vaccines. The Company's products mainly include adsorbed tetanus vaccine, Hib conjugate vaccine and tetanus toxoid concentrate stock solution. The Company's main customers are center for disease control and prevention (CDC) customers.

  • Revenue in CNY (TTM)500.05m
  • Net income in CNY-12.30m
  • Incorporated2009
  • Employees471.00
  • Location
    Chengdu Olymvax Biopharmaceuticals IncNo. 99 Tianxin Road, High-tech ZoneCHENGDU 611731ChinaCHN
  • Phone+86 2 869361198
  • Fax+86 2 869361100
  • Websitehttps://www.olymvax.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sinotherapeutics Inc368.86m76.25m3.92bn260.0051.433.27--10.630.16820.16820.81372.650.2753.085.831,418,710.005.69--6.09--51.77--20.67--9.09--0.00006--21.13---34.29------
Jiangsu Bioperfectus Technologies Co Ltd400.25m-314.32m3.99bn684.00--1.16--9.96-5.36-5.366.8358.770.09150.85921.57585,153.50-7.1925.41-8.3631.2663.2063.37-78.5332.866.05--0.08630.54-92.7211.81-120.45--2.43--
Shanghai Medicilon Inc1.17bn-172.33m4.00bn2.60k--1.62--3.41-1.24-1.249.1118.340.42056.631.64451,437.20-6.179.34-7.9711.7312.4836.71-14.6814.932.63--0.122920.18-17.6833.26-109.82--23.60--
Jinyao Pharmaceutical Co Ltd3.66bn107.59m4.01bn2.68k37.291.33--1.100.09840.09843.352.760.57382.289.371,365,219.002.331.914.173.4042.6146.334.063.310.758427.180.206444.402.559.28230.60-4.22-9.589.21
Chengdu Olymvax Biopharmaceuticals Inc500.05m-12.30m4.06bn471.00--4.53--8.12-0.0303-0.03031.232.210.33380.41971.081,061,669.00-1.223.17-1.704.6893.2993.00-3.647.441.92-3.900.25059.82-9.3845.40-33.94--56.47--
Hangzhou Alltest Biotech Co Ltd718.48m184.83m4.10bn1.09k22.221.05--5.712.332.339.0249.430.1652.136.17657,349.004.2423.354.5726.8346.8358.3425.6939.0710.16--0.005629.79-77.7332.59-84.7526.1972.77--
Hainan Huluwa Pharmaceutical Grop Co Ltd1.81bn94.97m4.13bn2.47k43.443.59--2.280.23740.23744.522.870.67212.883.81732,708.903.805.816.299.7850.3358.015.667.030.82457.040.524621.7425.7514.1324.291.1646.37--
Assure Tech Hangzhou Co Ltd511.29m160.91m4.15bn791.0025.810.8016--8.121.271.274.0240.750.07991.522.67646,379.602.5131.832.9438.9738.5665.8231.4747.868.26--0.016616.05-91.8425.18-95.3533.5178.77--
Data as of Jun 17 2024. Currency figures normalised to Chengdu Olymvax Biopharmaceuticals Inc's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

8.93%Per cent of shares held by top holders
HolderShares% Held
GF Fund Management Co., Ltd.as of 31 Dec 202317.30m6.00%
Orient Securities Asset Management Co. Ltd.as of 31 Dec 20232.62m0.91%
Fullgoal Fund Management Co., Ltd.as of 31 Dec 20232.54m0.88%
Bank of Communications Schroder Fund Management Co., Ltd.as of 31 Dec 2023653.72k0.23%
UBS SDIC Fund Management Co., Ltd.as of 30 Jun 2023586.82k0.20%
Hongde Fund Management Co., Ltd.as of 31 Dec 2023551.12k0.19%
Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023467.71k0.16%
Truvalue Asset Management Co. Ltd.as of 31 Dec 2023409.88k0.14%
China Asset Management Co., Ltd.as of 31 Dec 2023327.13k0.11%
Harvest Fund Management Co., Ltd.as of 31 Dec 2023283.64k0.10%
More ▼
Data from 30 Jun 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.